Monitor acute and short-term adverse effects

The manuals converge on the need for active observation of acute and short-term effects during and after psychedelic or related treatment. Across the extracts, the emphasis is on monitoring participants for immediate adverse reactions, documenting what happens, and following up after the session or dosing period. The Gasser study, for example, highlights acute and short-term adverse effects, including whether anything persists beyond 1 day, while the BPL-003-203 SAP focuses on post-dose reactivation events and their timing, emotional tone, and functional impact. The sources also agree that not all adverse effects are treated as equally serious, but they still require attention. The 5-MeO-DMT microdosing study distinguishes mild, self-resolving symptoms such as nausea or headache from persistent, worsening, or atypical symptoms, and the ibogaine study frames withdrawal and acute subjective distress as manageable but still requiring close observation. In the Gasser extract, the absence of treatment-related serious adverse events does not remove the need for monitoring, it reinforces it. They differ mainly in what they are watching for and how specific the monitoring is. The BPL-003-203 SAP is focused on reactivation phenomena and uses the ReAQ to capture occurrence, timing, emotional valence, functional impact, and narrative descriptions. By contrast, the Gasser study is broader and centred on acute and short-term adverse effects and serious adverse events, while the other two extracts emphasise transient side effects and withdrawal or tolerability during detoxification.